Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Luis Chu"'
Autor:
Christian Wülfing, A. Tubbs, Rick Wenstrup, J.S. de Bono, Klaus Pantel, Sandrine Macé, Joseph D. Schonhoft, Ayse Ozatilgan, Luis Chu, Eleni Efstathiou, Cora N. Sternberg, Karim Fizazi, R. de Wit, D. Castellano Gauna, Christine Geffriaud-Ricouard, Bertrand Tombal
Publikováno v:
Annals of Oncology. 32:S653-S654
Autor:
Luis Chukwuemeka Orakwe, Kingsley Nnaemeka Ogbu, Joseph Ikenna Ubah, Chike Pius Nwachukwu, Chinaza Rosemary Akamonye, Uchenna Peter Okoro
Publikováno v:
ASM Science Journal, Vol 17, Pp 1-8 (2022)
In this study, selected types of grasses were studied to determine their hydraulic roughness coefficient and to select the most suitable grass for erosion control. The experiments were performed in twelve trapezoidal open channels measuring 5 m x 0.1
Externí odkaz:
https://doaj.org/article/486ff79847c640eaa57d014edbefbb33
Autor:
Julio Hajdenberg, Tamila L. Kindwall-Keller, Brendan D. Curti, Charles A. Henderson, Jeffrey R. George, Wilson H. Miller, John D. Hainsworth, Luis Chu, Lisa Cupit, David F. McDermott, Chenghua Xia, Robert A. Figlin, Harry A. Drabkin, Sebastien J. Hotte, Walter M. Stadler, Marc S. Ernstoff, Jennifer J. Knox, Christopher W. Ryan, Janice P. Dutcher, Ronald M. Bukowski
Publikováno v:
Cancer. 116:1272-1280
BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. METHODS: In this nonrandomized, open-label expanded access program, 2504
Autor:
Yoshiko Aoyagi, Manoop S. Bhutani, Francesco Paolo D'Armiento, Jian-Zhong Di, Maurie Markman, Hiroto Kayashima, Nikolaos Androulakis, Toshiaki Watanabe, J. Legakis, Georgia Milaki, Jørn G. Stemland, Jennifer J. Knox, Jeffrey H. Lee, Julio Hajdenberg, Alfonso De Stefano, Marcella Giordano, John V. Brown, Keisuke Nakamura, Seiji Naito, Kazuyoshi Motomura, Isao Ikemoto, Kenzo Shimazu, Anna Crispo, Tamila L. Kindwall-Keller, Norikazu Masuda, Bram H. Goldstein, Kenichi Taguchi, Hajime Shibuya, J. Koutantos, Carsten Nieder, Eric M. Rohren, Brendan D. Curti, Yoshihisa Sakaguchi, J. Stathopoulos, Maria D'Armiento, John D. Hainsworth, Taiji Tsukamoto, Jodi J. Prochaska, S. Batzios, Pin Zhang, Ronald M. Bukowski, Hiroshi Yamamoto, Yuichi Takatsuka, Harry A. Drabkin, Qi Zheng, Ai-Zhong Wang, Eisuke Adachi, David F. McDermott, Mikio Namiki, Niki Karachaliou, Zhongxing Liao, Hideo Inaji, Sabino De Placido, Santosh B. Murthy, Chenghua Xia, Nikolaos Vardakis, Lisa N. Abaid, D. Trafalis, Mark Kozloff, Srikrishna V. Patnana, Christopher W. Ryan, Tetsuya Taguchi, Stephen G. Swisher, Yasushi Toh, Janice P. Dutcher, Fumine Tsukamoto, Nikolaos Ziras, Yu Wang, Wayne L. Hofstetter, Astrid Dalhaug, Yoshihiko Maehara, Wilson H. Miller, Lianchun Xiao, John P. Micha, Takeshi Okamura, Homer A. Macapinlac, Hiroyuki Fujimoto, Jaffer A. Ajani, Kazuyuki Wakita, Stefano Pepe, A. Armakolas, Fairooz F. Kabbinavar, Shinzaburo Noguchi, Axel Grothey, Michiyuki Usami, Wei Dong, Guanshan Zhu, Xuemei Wang, Takahiro Nakayama, Jordan Berlin, Wen-Ye Gu, Robert A. Figlin, Lisa Cupit, Jan Norum, Luis Chu, G.P. Stathopoulos, Vassilis Georgoulias, Lifang Hou, Hisae Iinuma, Kohri Yoneda, Akinobu Taketomi, Ken Shirabe, Antonia Kalykaki, Zhong-Zheng Zhu, Sarita Dubey, Charles A. Henderson, L. Cannella, Mark A. Rettenmaier, Mark Ashby, Amy P. Sing, Norifumi Harimoto, Janine K. Cataldo, Takashi Nomura, Marc S. Ernstoff, Walter M. Stadler, Takashi Morimoto, Andrew J. Gawron, Wen-Ming Cong, Aris Polyzos, Nikolaos Kentepozidis, Patrick J. Flynn, Chiara Carlomagno, Hideyuki Akaza, Mikio Kobayashi, C. Batziou, Stylianos Kakolyris, Sebastien J. Hotte, Yoshiaki Nakano
Publikováno v:
Oncology. 78:I-IV
Autor:
Luis Chu, Paul M. Hyman, Jacob D. Soumerai, Steven P. Treon, Johannes C. Nunnink, Joseph J. Kash, Zachary R. Hunter, Christopher J. Patterson, Nikhil C. Munshi, Ari David Baron, Paul Musto, Terenig O. Terjanian, Leukothea Ioakimidis, David J. Sharon, Andrew R. Branagan, Elena L. Nawfel, Kenneth C. Anderson
Publikováno v:
Clinical Cancer Research. 15:355-360
Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinem
Autor:
Mark W. Pasmantier, Andrew R. Branagan, Henry Sonneborn, Bryan Ciccarelli, Jacob D. Soumerai, Zachary R. Hunter, David R. Lovett, Leukothea Ioakimidis, Kenneth C. Anderson, John M. Howard, Robert B. Cooper, Paul Musto, Hans Boedeker, Steven P. Treon, Alan Rauch, Cynthia Chua, Lawrence Garbo, Luis Chu, Maria Moore, John M. Hill, Frederick M. Briccetti, Stephen H. Nantel, Evdoxia Hatjiharissi, Harvey Zimbler, Christopher J. Patterson
Publikováno v:
Blood. 112:4452-4457
Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended
Autor:
James Essell, Jesus G. Berdeja, Luis Chu, Ralph V. Boccia, Todd M. Bauer, P. Acs, Edward Arrowsmith, Ian W. Flinn
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e70-e71
Background Despite significant advances, multiple myeloma is an incurable plasma cell disorder with an eventual fatal outcome. In newly diagnosed MM, combinations of bortezomib, steroids and alkylating agents, such as melphalan and prednisone, have a
Publikováno v:
BMC Molecular and Cell Biology, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Sequence-specific transcription factors (TFs) recognize motifs of related nucleotide sequences at their DNA binding sites. Upon binding at these sites, TFs regulate critical molecular processes such as gene expression. It is widely assumed t
Externí odkaz:
https://doaj.org/article/1514fc4ba0f14af19e1012d0b3401bfe
Autor:
Eric P. Winer, Gloria Broadwater, Leonard R. Prosnitz, George Leight, Gray Bowen, Marc A. Warmuth, Luis Chu, Bercedis Peterson
Publikováno v:
Cancer. 83:1362-1368
BACKGROUND Axillary lymph node dissection is commonly performed as part of the primary management of breast carcinoma. Its value in patient management, however, has recently been questioned. Few studies exist that document long term complications. ME